In vivo HABP2 silencing by small interfering RNA attenuated LPS-mediated lung injury and hyperpermeability, indicating a possible therapeutic strategy for bacterial pneumonia in those with AUD-induced barrier dysfunction. The gene discussed is HABP2; the disease is bacterial pneumonia.